echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Cell Prolif: LncRNA-AK137033 regulates the Wnt signaling pathway through DNA methylation and inhibits the osteogenic potential of adipose-derived stem cells in diabetic osteoporosis

    Cell Prolif: LncRNA-AK137033 regulates the Wnt signaling pathway through DNA methylation and inhibits the osteogenic potential of adipose-derived stem cells in diabetic osteoporosis

    • Last Update: 2022-01-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background: Diabetes mellitus is a systemic metabolic disease characterized by hyperglycemia
    .
    This systemic disorder of glucose metabolism has a severe negative impact on the skeletal system, leading to a serious complication of the skeletal and joint system, namely diabetic osteoporosis (DOP)

    .
    In addition to the microenvironment of hyperglycemia, DOP patients also have the characteristics of bone microstructure damage, decreased bone strength, fracture susceptibility, and poor healing of bone defects

    .
    For bone defects in DOP patients, current treatments are suboptimal
    .
    With the rapid development of tissue engineering,
    bone tissue engineering includes scaffold materials and stem cells
    .
    Adipose-derived stem cells (ASCs) are one of the most widely used seed cells in bone tissue engineering

    .
    However, our previous study showed that diabetic osteoporotic adipose-derived stem cells (DOP-ASCs) had lower osteogenic potential compared with control adipose-derived stem cells (CON-ASCs), limiting their use in fractures and bone defects in DOP patients application in therapy
    .
    Therefore, the molecular mechanism of the decreased osteogenic ability of DOP-ASCs needs to be further explored to find potential targets for the treatment of bone defects in DOP patients

    .

    Diabetes is a systemic metabolic disease characterized by hyperglycemia
    .
    This systemic disorder of glucose metabolism has a severe negative impact on the skeletal system, leading to a serious complication of the skeletal and joint system, namely diabetic osteoporosis (DOP)

    .
    In addition to the microenvironment of hyperglycemia, DOP patients also have the characteristics of bone microstructure damage, decreased bone strength, fracture susceptibility, and poor healing of bone defects

    .
    Bone tissue engineering includes scaffold materials and stem cells
    .
    Adipose-derived stem cells (ASCs) are one of the most widely used seed cells in bone tissue engineering

    .

    Objective: Bone tissue engineering based on adipose stem cells (ASCs) is expected to become a new method for the treatment of diabetic osteoporosis (DOP) with bone defects
    .
    However, compared with control ASCs, the osteogenic capacity of DOP-ASCs was reduced, increasing the difficulty of bone remodeling in patients with DOP

    .
    Furthermore, the reason for the poor osteogenesis of ASCs in a hyperglycemic microenvironment has not been elucidated

    .
    Therefore, this study explored the molecular mechanism of the decreased osteogenic potential of DOP-ASCs from the perspective of epigenetics, and provided possible therapeutic targets for bone repair in patients with DOP and bone defects

    .

    METHODS: A mouse model of DOP was established
    .
    CON-ASCs and DOP-ASCs were isolated from CON and DOP mice, respectively

    .
    The expression of AK137033 in CON-ASCs and DOP-ASCs was regulated in vitro by AK137033 small interfering RNA (siRNA) and AK137033 overexpression plasmid

    .
    AK137033 was knocked down or overexpressed in CON-ASCs and DOP-ASCs, respectively, using lentiviruses carrying shRNA-AK137033 or AK137033 cDNA

    .
    Hematoxylin and eosin (H&E), Masson's, Alizarin red, alkaline phosphatase (ALP) staining, micro-computed tomography (micro-CT), flow cytometry, qPCR, western blotting, The functional changes of ASCs were analyzed by immunofluorescence and bisulfite-specific PCR (bisulfite-specific PCR, BSP)

    .

    Results: The DOP mouse model was successfully established
    .
    Compared with CON-ASCs, the expression of AK137033, sFrp2 promoter DNA methylation level, Wnt signaling pathway markers, and osteogenic differentiation potential were all decreased in DOP-ASCs

    .
    In vitro experiments showed that silencing AK137033 inhibited the Wnt signaling pathway and the osteogenic ability of CON-ASCs by reducing the DNA methylation level in the sFrp2 promoter region

    .
    Furthermore, overexpression of AK137033 in DOP-ASCs abrogated these DOP-induced changes

    .
    The same results were obtained in vivo

    .

    Conclusion: LncRNA-AK137033 inhibits the osteogenic potential of DOP-ASCs by regulating the level of DNA methylation in the sFrp2 promoter region and regulating the Wnt signaling pathway
    .
    This study provides an important reference for finding new targets for the treatment of bone defects in DOP patients

    .

    LncRNA-AK137033 inhibits the osteogenic potential of DOP-ASCs by regulating the DNA methylation level in the sFrp2 promoter region and regulating the Wnt signaling pathway
    .
    This study provides an important reference for finding new targets for the treatment of bone defects in DOP patients

    .

    Original source: Peng S, Gao Y, Shi S, et al.
    LncRNA-AK137033 inhibits the osteogenic potential of adipose-derived stem cells in diabetic osteoporosis by regulating Wnt signaling pathway via DNA methylation.
      Cell Prolif 2021 Dec 24.

    LncRNA-AK137033 inhibits the osteogenic potential of adipose-derived stem cells in diabetic osteoporosis by regulating Wnt signaling pathway via DNA methylation.


    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.